title: Patient-derived induced pluripotent stem cells in cancer research and precision oncology.
abstract: Together with recent advances in the processing and culture of human tissue, bioengineering, xenotransplantation and genome editing, Induced pluripotent stem cells (iPSCs) present a range of new opportunities for the study of human cancer. Here we discuss the main advantages and limitations of iPSC modeling, and how the method intersects with other patient-derived models of cancer, such as organoids, organs-on-chips and patient-derived xenografts (PDXs). We highlight the opportunities that iPSC models can provide beyond those offered by existing systems and animal models and present current challenges and crucial areas for future improvements toward wider adoption of this technology.
authors.affiliation: Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.|The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.|The Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.|Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
authors.forename: Eirini P
authors.identifier: 0000-0001-7002-417X
authors.initials: EP
authors.lastname: Papapetrou
mesh_terms: D000818:Animals; D035843:Biomedical Research; D002454:Cell Differentiation; D065150:Cellular Reprogramming; D019008:Drug Resistance, Neoplasm; D006801:Humans; D057026:Induced Pluripotent Stem Cells; D008495:Medical Oncology; D009368:Neoplasm Transplantation; D009369:Neoplasms; D014411:Neoplastic Stem Cells; D009940:Organoids; D057285:Precision Medicine; D057170:Translational Research, Biomedical; D014183:Transplantation, Heterologous